HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boucek, R. J. Articles by Fleischer, S. Search for Related Content PubMed PubMed Citation Articles by Boucek, R. J., Jr Articles by Fleischer, S. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 262, Issue 33, 15851-15856, 11, 1987

The major metabolite of doxorubicin is a potent inhibitor of membrane- associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions

RJ Boucek Jr, RD Olson, DE Brenner, EM Ogunbunmi, M Inui and S Fleischer
Department of Pediatrics/Biochemistry, Vanderbilt University, Nashville, Tennessee 37232.

Doxorubicin (adriamycin) is a highly effective cancer chemotherapeutic drug but its clinical utility is limited by its cardiotoxicity. Doxorubicinol, the major metabolite of doxorubicin, is up to 10 times more potent than doxorubicin at inhibiting isometric contraction of the papillary muscle isolated from the right ventricle of rabbit heart. Doxorubicinol also increases resting tension of isolated cardiac muscle indicative of incomplete relaxation between contractions, a characteristic of doxorubicinol but not of doxorubicin. This study assesses the effect(s) of doxorubicinol on a variety of ion pumps which may explain, in part, the action of the metabolite in the intact muscle. We find the doxorubicinol is a potent inhibitor (IC50 less than 5 micrograms/ml) of calcium-stimulated ATPase activity of sarcoplasmic reticulum from canine heart and rabbit skeletal muscle. At comparable levels, doxorubicinol is also a potent inhibitor of (Na + K)-ATPase of cardiac sarcolemma and the Mg-dependent ATPase activity referable to the F0F1 proton pump of mitochondria. For each of these ion pumps, doxorubicinol is at least 80 times more potent an inhibitor than doxorubicin. Doxorubicinol, between 10 and 50 micrograms/ml, increases resting tension up to 4-fold in isolated papillary muscles cyclically contracting at 30 times/min. Resting stress is relatively insensitive to doxorubicin. Thus, doxorubicinol is a potent inhibitor of several key cationic pumps that directly or indirectly regulate cell calcium and inhibits relaxation in the isolated fiber preparation. These observations add a new dimension to understanding the cardiotoxicity of doxorubicin.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. H. Takahashi, O. S. Bains, T. A. Pfeifer, T. A. Grigliatti, R. E. Reid, and K. W. Riggs Aldo-Keto Reductase 1C2 Fails to Metabolize Doxorubicin and Daunorubicin in Vitro Drug Metab. Dispos., June 1, 2008; 36(6): 991 - 994. [Abstract] [Full Text] [PDF]

				O. S. Bains, R. H. Takahashi, T. A. Pfeifer, T. A. Grigliatti, R. E. Reid, and K. W. Riggs Two Allelic Variants of Aldo-Keto Reductase 1A1 Exhibit Reduced in Vitro Metabolism of Daunorubicin Drug Metab. Dispos., May 1, 2008; 36(5): 904 - 910. [Abstract] [Full Text] [PDF]

				L. Xia, L. Jaafar, A. Cashikar, and H. Flores-Rozas Identification of Genes Required for Protection from Doxorubicin by a Genome-Wide Screen in Saccharomyces cerevisiae Cancer Res., December 1, 2007; 67(23): 11411 - 11418. [Abstract] [Full Text] [PDF]

				G. L. Forrest, B. Gonzalez, W. Tseng, X. Li, and J. Mann Human Carbonyl Reductase Overexpression in the Heart Advances the Development of Doxorubicin-induced Cardiotoxicity in Transgenic Mice Cancer Res., September 1, 2000; 60(18): 5158 - 5164. [Abstract] [Full Text]

				S.-H. Kim and C.-C. Chu In Vitro Release Behavior of Dextran-Methacrylate Hydrogels Using Doxorubicin and other Model Compounds J Biomater Appl, July 1, 2000; 15(1): 23 - 46. [Abstract] [PDF]

				E. L. de Beer, A. E. Bottone, J. van der Velden, and E. E. Voest Doxorubicin Impairs Crossbridge Turnover Kinetics in Skinned Cardiac Trabeculae after Acute and Chronic Treatment Mol. Pharmacol., June 1, 2000; 57(6): 1152 - 1157. [Abstract] [Full Text]

				G. MINOTTI, G. CAIRO, and E. MONTI Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J, February 1, 1999; 13(2): 199 - 212. [Abstract] [Full Text]

				M. A Movsesian and R. H.G Schwinger Calcium sequestration by the sarcoplasmic reticulum in heart failure Cardiovasc Res, February 1, 1998; 37(2): 352 - 359. [Full Text] [PDF]

				K. Shan, A. M. Lincoff, and J. B. Young Anthracycline-Induced Cardiotoxicity Ann Intern Med, July 1, 1996; 125(1): 47 - 58. [Abstract] [Full Text]

				Y.-X. Wang and M. Korth Effects of Doxorubicin on Excitation-Contraction Coupling in Guinea Pig Ventricular Myocardium Circ. Res., April 1, 1995; 76(4): 645 - 653. [Abstract] [Full Text]